These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12789171)

  • 21. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris.
    Gottlieb AB; Masud S; Ramamurthi R; Abdulghani A; Romano P; Chaudhari U; Dooley LT; Fasanmade AA; Wagner CL
    J Am Acad Dermatol; 2003 Jan; 48(1):68-75. PubMed ID: 12522373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions.
    Spertino J; Lopez-Ferrer A; Vilarrasa E; Puig L
    J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1514-21. PubMed ID: 25493314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment.
    DE Oliveira JP; Levy A; Morel P; Guibal F
    J Dermatol; 2008 Sep; 35(9):575-80. PubMed ID: 18837702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
    Puig L
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice.
    Shear NH; Hartmann M; Toledo-Bahena M; Katsambas A; Connors L; Chang Q; Yao R; Nograles K; Popmihajlov Z;
    Br J Dermatol; 2014 Sep; 171(3):631-41. PubMed ID: 24673357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab monotherapy for refractory psoriasis: preliminary results.
    Cassano N; Loconsole F; Amoruso A; Coviello C; Filieri M; Filotico R; Del Vecchio S; Vena GA
    Int J Immunopathol Pharmacol; 2004; 17(3):373-80. PubMed ID: 15461871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of severe refractory psoriasis with infliximab].
    Mahiques Santos L; Martínez-Menchón T; Sánchez Carazo JL; Oliver Martínez V; Soriano Navarro CJ; Fortea Baixauli JM
    Med Clin (Barc); 2004 Nov; 123(17):657-8. PubMed ID: 15563800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.
    Chaudhari U; Romano P; Mulcahy LD; Dooley LT; Baker DG; Gottlieb AB
    Lancet; 2001 Jun; 357(9271):1842-7. PubMed ID: 11410193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab.
    Schopf RE; Aust H; Knop J
    J Am Acad Dermatol; 2002 Jun; 46(6):886-91. PubMed ID: 12063486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice.
    Shear NH; Hartmann M; Toledo-Bahena ME; Gilbert M; Katsambas A; Yao R; Popmihajlov Z
    Qual Life Res; 2016 Aug; 25(8):2031-40. PubMed ID: 26869477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
    Papp K; Leonardi C; Menter A; Thompson EH; Milmont CE; Kricorian G; Nirula A; Klekotka P
    J Am Acad Dermatol; 2014 Dec; 71(6):1183-1190.e3. PubMed ID: 25313095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.
    Bissonnette R; Luger T; Thaçi D; Toth D; Messina I; You R; Guana A; Fox T; Papavassilis C; Gilloteau I; Mrowietz U
    Br J Dermatol; 2017 Oct; 177(4):1033-1042. PubMed ID: 28580579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of the treatment of psoriasis with infliximab.
    Vamvouris T; Hadi S
    Rev Recent Clin Trials; 2006 Sep; 1(3):201-5. PubMed ID: 18473973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Infliximab: patients selection].
    Puig L
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():23-9. PubMed ID: 19080988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial.
    Yang HZ; Wang K; Jin HZ; Gao TW; Xiao SX; Xu JH; Wang BX; Zhang FR; Li CY; Liu XM; Tu CX; Ji SZ; Shen Y; Zhu XJ
    Chin Med J (Engl); 2012 Jun; 125(11):1845-51. PubMed ID: 22884040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
    Reich K; Nestle FO; Wu Y; Bala M; Eisenberg D; Guzzo C; Li S; Dooley LT; Griffiths CE
    Eur J Dermatol; 2007; 17(5):381-6. PubMed ID: 17673380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infliximab for psoriasis.
    Gottlieb AB
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S112-7. PubMed ID: 12894134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
    Papp KA; Bressinck R; Fretzin S; Goffe B; Kempers S; Gordon KB; Caro I; Walicke PA; Wang X; Menter A;
    Int J Dermatol; 2006 May; 45(5):605-14. PubMed ID: 16700803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.